[IP] Has anyone here heard about this?? *** ORSENSE'S NON-INVASIVE GLUCOSE MONITOR
IS THIS BE TOO GOOD TO BE TRUE??????????
IF IT WORKS OUT, I MOST DEFINITELY WANT ONE!!!!!!!!!!
..........................OR COULD THIS BE ANOTHER "GLUCOWATCH?????"
WHAT DO YOU THINK ABOUT THIS???????????
MM 515 4/05
Orsense -non-invasive (video)
There's video too: http://www.israelhightech.tv./
Israeli device monitors diabetes - the painless way (SEE EXCLUSIVE VIDEO
Orsense's non-invasive glucose monitor that allows a diabetic patient to
test his or her blood glucose levels without spilling a drop of blood.
Doctors agree that the most essential way to treat diabetes and prevent
long-term health complications is for every patient to manage their disease
carefully by testing glucose levels regularly. Sounds easy right? But the
majority of diabetic patients are doing no such thing. Instead of testing
themselves the recommended four to seven times a day, many diabetics are
testing themselves just once a day, while some are not bothering with
testing at all.
So why would anyone want to risk a whole list of health problems ranging
from impotence, blindness, kidney failure, nerve degeneration,
cardiovascular malfunction, amputation, and even death just to avoid a test?
The problem is the test itself - a painful pinpick of blood from the finger.
Not only is it an unpleasant experience, especially when repeated month
after month, year after year, but also it is also cumbersome, and unsafe.
Now an Israeli company, OrSense, has come up with a solution - a
non-invasive glucose monitor that allows a diabetic patient to test his or
her blood glucose levels without spilling a drop of blood.
Diabetes is a devastating disease with no known cure. In developed countries
it is the fourth leading cause of death, and has now been recognized as a
global epidemic, with the potential to cause a worldwide healthcare crisis.
Currently some 200 million people worldwide suffer from diabetes, and the
International Diabetes Federation estimates that this figure will rise to
333 million by the year 2025.
America now has over 21 million diabetics - some seven percent of the total
population. Of this an estimated 14.6 million have been diagnosed with the
condition, leaving well over six million unaware that they are suffering
from the disease. A further 41 million Americans suffer from impaired
glucose intolerance, a condition that leads to diabetes. In many of these
people, the complications of diabetes may already be occurring, causing
long-term damage to the body.
The result of this is that in the US one of every ten healthcare dollars is
spent on treating or managing diabetes. In 2002, the total economic cost for
the year of diabetes healthcare was estimated at $132 billion.
Decades of research confirm that obesity is an important contributing factor
in diabetes. Eighty percent of Type 2 diabetics are also obese or
overweight. The health care community forecasts that if the obesity epidemic
in the US continues unchecked, the diabetes epidemic will continue to grow
at an alarming rate.
OrSense's monitor, the NBM-200G, is based on "Occlusion Spectroscopy",
OrSense's proprietary measurement technology and is designed to
non-invasively measure multiple significant blood parameters such as
glucose, hemoglobin, SpO2, etc.
A ring-shaped probe is applied to the patient's finger, gently stopping the
flow of blood. The device generates a strong optical signal across the
finger yielding a high blood driven signal-to-noise ratio. Analysis of this
signal provides the sensitivity necessary to measure blood glucose and other
analyte concentrations without the need to draw blood with a fingerstick
test. Results are available within 30 seconds, and the measurement can be
repeated painlessly and rapidly any number of times, and even continuously.
"OrSense stands out from competitors in this arena in because it does not
try to measure blood in its natural state of circulation," says Lior
Ma'ayan, the CEO of OrSense. "Our technology is based on creating a new
dynamic in the blood - looking at it, not in its normal behavior, but
Over the last 24 months, OrSense has carried out four clinical trials in
five different locations across Israel. Over 300 patients were involved in
the trials, and over 100,000 measurements were taken. The study consisted of
three phases: one focused on low glucose levels and two additional trials
that simulated home use, including nighttime measurements.
Results show that readings obtained by the OrSense device were as accurate
as those obtained using regular invasive testing of type I and type II
diabetic patients under home conditions. The device was also found to offer
very good quality of performance in the low glucose range.
The results of these trials were presented to the European Association of
Diabetes, the International Symposium on Intensive Care and Emergency
Medicine, and the American Diabetes Association's 66th Scientific Sessions
which was held in Washington DC in June. This is considered to be one of the
most important conferences in the field, and OrSense was one of only two
companies to present clinical results in non-invasive blood sugar testing at
In his presentation to the Washington conference, Professor Avraham Karasik,
director of the endocrinology institute at the Sheba Medical Center, Tel
Hashomer, and the principal investigator of the study, said, "We believe
that OrSense's glucose monitoring system is set to become the system for
real-time blood sugar monitoring of diabetes patients under home
The device is already well advanced in the regulatory process in both Europe
and the US. "We are in the final stage of data collection for CE approval,"
Ma'ayan told ISRAEL21c.
The company also plans to carry out a pivotal trial in order to receive FDA
Ma'ayan says he believes the device will reach the European and US markets
early in 2008. Though there are a number of companies, including other
Israeli companies, in the race to produce the first non-invasive glucose
monitor, Ma'ayan feels confident that he is in the front of the pack.
While the glucose monitor is OrSense's main product, the company has also
developed the NBM-100, a non-invasive hemoglobin/hematocrit monitor. The
NBM-100 has already been granted CE approval and goes on sale in the UK and
Europe this year. It is now in trials in the US and the company expects it
to win FDA approval soon.
The hemoglobin monitor can detect anemia and gives an early diagnosis of
blood loss in ER or operating room environments. "This is a life-saving
tool," says Ma'ayan. "Studies have shown that doctors are waiting for a
device like this because in the past they have lost patients due to hidden
The device can also be used before blood donation to painlessly check
hemoglobin levels in potential donors. "Today the test for hemoglobin levels
is often more painful that the donation itself because there are more nerves
in the tip of the finger than in a venous location," admits Ma'ayan.
OrSense was founded in 1996 by Dr. Alex Sternberg and Dr. Ilya Fine. Until
now the company has raised $28 million. It's last round, of $6.2 million,
was held in February this year.
Principal investors in the company include Israel Healthcare Ventures, the
Lewis Trust Group, STAR Ventures, Carlo Salvi and other individual
investors. The Office of the Chief Scientist also invested $4 million in the
company. OrSense employs 30, and is based at the Weizmann Science Park in
Ness Ziona. The company has 20 granted patents worldwide, and over 25
additional applications in the process.
"Glucose monitoring is the essential tool for diabetics to control and
regulate their illness, but the one clear barrier to this is the current
mode of monitoring," says Ma'ayan. "OrSense's non-invasive blood glucose
monitor holds out the promise of a dramatic improvement in the quality of
life of millions of diabetics worldwide."
(See Exclusive Video on Orsense from IsraelHighTech.TV).
Call friends with PC-to-PC calling -- FREE
for HELP or to subscribe/unsubscribe/change list versions,